Eyenovia, Inc. (NASDAQ:EYEN) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 50,000 shares, a drop of 38.6% from the December 15th total of 81,400 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 219,800 shares, the short-interest ratio is presently 0.2 days.
Large investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in shares of Eyenovia by 11.9% during the third quarter. BlackRock Inc. now owns 49,255 shares of the company’s stock worth $153,000 after purchasing an additional 5,257 shares during the last quarter. National Asset Management Inc. bought a new stake in shares of Eyenovia during the third quarter worth $41,000. Virtu Financial LLC bought a new stake in shares of Eyenovia during the third quarter worth $51,000. Finally, Shone Asset Management LLC bought a new stake in shares of Eyenovia during the third quarter worth $69,000. Hedge funds and other institutional investors own 6.32% of the company’s stock.
NASDAQ EYEN traded down $0.17 during midday trading on Thursday, hitting $6.44. The company had a trading volume of 2,006 shares, compared to its average volume of 324,724. The firm has a fifty day simple moving average of $5.05 and a two-hundred day simple moving average of $3.83. Eyenovia has a fifty-two week low of $1.11 and a fifty-two week high of $7.25. The company has a quick ratio of 3.77, a current ratio of 3.77 and a debt-to-equity ratio of 0.02. The stock has a market cap of $160.25 million, a price-to-earnings ratio of -6.01 and a beta of 2.09.
Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.05). As a group, equities analysts predict that Eyenovia will post -0.99 earnings per share for the current year.
EYEN has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 target price (down previously from $7.00) on shares of Eyenovia in a report on Friday, October 23rd. Zacks Investment Research downgraded shares of Eyenovia from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Roth Capital decreased their price target on shares of Eyenovia from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Eyenovia currently has a consensus rating of “Hold” and a consensus target price of $9.94.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments.
Featured Article: What does it mean to hold a stock in street name?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.